Submitted by GAtherton on 19 October 2015
The European Commission (EC) has approved Basilea Pharmaceutica’s isavuconazole (Cresemba) product to treat invasive aspergillosis and mucormycosis.
The company plans to start a commercial launch of the drug in major European countries in early next year.
Earlier this year, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the regulatory approval of isavuconazole in the European Union (EU) for the treatment in adults with invasive aspergillosis and mucormycosis in patients for whom amphotericin B is inappropriate.
The marketing authorization for isavuconazole will be valid in all 28 EU member states, as well as in Iceland, Liechtenstein and Norway.
News archives
Showing 10 posts of 953 posts found.
-
Title
Date
